Skip to main content

COVID-19 leaves large cancer screening deficit in USA

USA outline_flag

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.


People with inflammatory diseases may have impaired antibody response to COVID-19 vaccination


SARS-CoV-2 vaccination “essentially works” in people with immune-mediated inflammatory diseases, but humoral immune responses may be delayed and reduced, researchers report.

Headlines from across medwireNews

13-05-2021 | Oncology | News | Article

Real-world pneumonitis rates with pembrolizumab–chemotherapy exceed clinical trial data

A Japanese real-world study has found higher rates of pneumonitis with first-line pembrolizumab plus chemotherapy among patients with advanced nonsquamous non-small-cell lung cancer than previously reported in clinical trials.

13-05-2021 | Rheumatology | News | Article

COAST-Y supports continued ixekizumab treatment for patients with axSpA

Patients with axial spondyloarthritis who continue treatment with ixekizumab are less likely to experience flares than those who discontinue the IL-17A inhibitor, trial results suggest.

12-05-2021 | Oncology | News | Article

Low cardiac event rates with dual HER2 blockade in early breast cancer

The BERENICE investigators report a low incidence of cardiac events with the use of pertuzumab–trastuzumab-based neoadjuvant and adjuvant regimens in patients with HER2-positive, early breast cancer after 5 years of follow-up.

12-05-2021 | Rheumatology | News | Article

NOR-DRUM, ARCTIC REWIND trials evaluate tailored DMARD strategies

Findings from two Norwegian trials published in JAMA do not support routine therapeutic drug monitoring with biologics or dose reduction of conventional DMARDs in patients with inflammatory diseases.

12-05-2021 | Oncology | News | Article

Breast cancer HER2-low status evolution revealed

Paired analysis of primary and relapsed breast cancer specimens shows that many HER2-negative patients switch between HER2-low and HER2-0 expression during disease progression.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits